The global companion diagnostics market is on track to reach $6 billion by 2030, powered by the rapid expansion of precision oncology and a growing body of evidence showing that biomarker-guided treatment selection delivers better clinical and economic outcomes than conventional approaches. The forecast period covered in Roots Analysis’s latest research edition spans 2019 to 2030, capturing more than a decade of structural change in how drugs are developed, approved, and deployed alongside matched diagnostics. With over 130 companion diagnostic tests already commercially available and more than 150 partnership deals inked since 2014, the sector is no longer a niche adjunct to drug development; it is a core pillar of modern medicine.
To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/companion-diagnostics-market-2nd-edition-2019-2030/request-sample.html
MARKET OVERVIEW
Companion diagnostics are a class of in vitro diagnostic devices that provide information necessary for the safe and effective use of a specific pharmaceutical or biological product. They work by identifying the molecular or genetic signatures of a patient’s disease, allowing physicians to match treatments to the patients most likely to respond. This is not a theoretical benefit. Approximately 50% of prescribed drugs fail to show adequate clinical benefits in unselected patient populations, and adverse drug reactions rank as the fourth leading cause of death in the United States. By stratifying patients before treatment begins, companion diagnostics reduce unnecessary exposure, cut costs across the care pathway, and give clinical trials a far better chance of success.
The case for companion diagnostics in drug development is equally compelling. A study spanning approximately 200 pharmacological interventions across 670 clinical trials found that only about 11% of lead compounds successfully navigate all development phases to reach approval. The same research showed that integrating biomarker-based patient stratification into trial design produced a sixfold increase in success rates and reduced clinical trial costs by nearly 60%. Those figures explain why pharmaceutical companies are investing heavily in co-development partnerships with diagnostic firms, and why the companion diagnostics market has become a strategic priority rather than a regulatory formality.
Since the 1998 approval of the HercepTest for identifying patients eligible for trastuzumab therapy, the field has grown to encompass more than 50 approved companion diagnostics covering oncology, infectious diseases, neurological disorders, and metabolic conditions. Recent regulatory milestones and industry collaborations signal that this growth is accelerating, not plateauing.
KEY GROWTH DRIVERS
Rising Clinical and Commercial Demand for Precision Oncology. Oncology accounts for the dominant share of the companion diagnostics market, and the volume of targeted cancer therapies under development continues to grow. Cancers of the breast, lung, colon, and blood, among others, each harbor distinct molecular subpopulations that respond differently to the same drug. Companion diagnostics make those distinctions clinically actionable, and regulatory agencies in the US and Europe now regularly require or strongly encourage their co-approval with new targeted therapies.
Expanding Application of Next-Generation Sequencing Assays. NGS-based companion diagnostics have moved from academic research into routine clinical practice. In September 2025, Illumina partnered with multiple pharmaceutical companies to extend companion diagnostic development on its TruSight Oncology 500 ctDNA platform, enabling tumor-agnostic genomic profiling across cancer types. This kind of platform-level diagnostic capacity, which can interrogate hundreds of alterations simultaneously, is opening new commercial opportunities that single-biomarker IHC or PCR tests cannot address.
Strategic Alliances Linking Drug Developers and Diagnostic Firms. More than 150 partnership deals have been signed since 2014, reflecting how central the co-development model has become. In January 2026, Guardant Health announced a collaboration with Merck to develop companion diagnostics using the Guardant Infinity liquid biopsy platform, targeting biomarker discovery, trial enrollment, and real-world evidence generation for Merck’s oncology portfolio. These alliances reduce duplicated R&D investment and compress timelines from biomarker discovery to clinical deployment.
AI Integration Into Diagnostic Development Pipelines. In October 2025, Lunit partnered with Agilent Technologies to develop AI-powered companion diagnostics that combine Lunit’s image analysis algorithms with Agilent’s IHC assays, enabling more precise biomarker detection and patient stratification at scale. AI integration is improving both the sensitivity and the throughput of companion diagnostic workflows, making the technology practical for broader clinical settings beyond major academic centers.
Regulatory Activity Sustaining Commercial Momentum. In March 2026, the FDA approved Agilent Technologies’ PD-L1 IHC 22C3 pharmDx test as a companion diagnostic to identify esophageal and gastroesophageal junction carcinoma patients suitable for Merck’s KEYTRUDA. Such approvals create immediate, durable commercial demand tied directly to the sales trajectory of the linked therapy, providing a revenue model that is more predictable than many other diagnostics categories.
MARKET SEGMENTATION
The companion diagnostics market segments across multiple dimensions, including therapeutic area, assay technique, sample type, and geography. By therapeutic area, oncological disorders form the clear market leader, with breast cancer, non-small cell lung cancer, colorectal cancer, leukemia, lymphoma, melanoma, and ovarian cancer among the specific indications driving volume. Non-oncological applications, including Alzheimer’s disease and HIV/AIDS diagnostics, represent a smaller but growing portion of the total addressable market as biomarker science matures beyond cancer. The report covers three forecast scenarios, conservative, base, and optimistic, providing flexibility in planning across different regulatory and adoption timelines.
By assay technique, the market covers in situ hybridization (ISH), immunohistochemistry (IHC), next-generation sequencing (NGS), polymerase chain reaction (PCR), and other emerging methods. NGS-based tests are gaining share most quickly, given their capacity for multi-analyte profiling and their alignment with tumor-agnostic regulatory pathways. By sample type, tumor tissue remains the most common specimen, but liquid biopsy approaches using blood and urine-based cfDNA assays are gaining clinical acceptance, as illustrated by Predicine’s September 2025 FDA submission for a urine-based NGS companion diagnostic in bladder cancer.
To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/companion-diagnostics-market-2nd-edition-2019-2030/request-quote.html
REGIONAL INSIGHTS
The United States holds the largest share of the companion diagnostics market, a position sustained by the FDA’s active co-approval framework for drugs and their matched diagnostics, substantial NIH and private investment in precision medicine infrastructure, and a pharmaceutical industry concentrated in the country that funds companion diagnostic co-development at scale. The US is also the primary site of the most commercially significant drug-diagnostic pairs, from PD-L1 immunotherapy tests to KRAS profiling assays, which generate recurring test volumes tied to ongoing treatment decisions.
Europe, and specifically the EU5 countries, represents the second major market, supported by EMA alignment with precision medicine policies and expanding reimbursement frameworks for biomarker-guided therapy selection. Japan, China, and Australia round out the geographic coverage in the Roots Analysis model, with China drawing particular attention as an emerging high-volume market where local diagnostic developers are building capacity and domestic pharma companies are forming co-development partnerships with global players to access NGS-based companion diagnostic technology.
COMPETITIVE LANDSCAPE
Key companies profiled in the companion diagnostics market report include Roche, Agilent Technologies, Abbott, QIAGEN, Myriad Genetics, and Foundation Medicine, along with a searchable database of additional providers worldwide. The competitive dynamic in this market balances concentration at the top, where Roche holds an extensive portfolio of approved tests tied to major oncology drugs, against meaningful disruption from genomics specialists and liquid biopsy innovators that are extending companion diagnostic capability beyond tissue-based testing. The main battleground is platform breadth and speed to regulatory approval, as pharma partners increasingly prefer diagnostic firms that can offer multi-analyte NGS platforms with an established FDA submission track record. Intellectual property around assay design and biomarker validation, rather than pricing alone, is the primary differentiator for firms seeking long-term co-development contracts.
Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/companion-diagnostics-market-2nd-edition-2019-2030/251.html
Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
This release was published on openPR.